Why take this course
Only about one in three people with rifampicin-resistant or multidrug-resistant TB are known to be getting the treatment they need. It is important to expand access to the WHO-recommended, fully oral treatment regimens.
This e-course will guide you through the essentials of latest existing WHO guidelines and policy recommendations on drug-resistant TB (DR-TB). You will also learn more about the rationale behind the WHO recommendations for the management of DR-TB, implementation considerations for different regimens for eligible patient groups, adjunctive treatment, the active TB drug safety monitoring and management framework, and the analysis and interpretation of performance indicators.
The e-course is intended for people who provide guidance on implementing WHO recommendations on TB at country level; for example, national programme managers, technical staff at ministries of health, WHO staff, staff of technical agencies, consultants and anyone else serving a similar role in countries and major subnational units.
It is assumed that you have experience working in TB and are familiar with WHO TB guidelines.
This e-learning course is a comprehensive, self-paced, online course that follows the content of the WHO operational handbook on tuberculosis. Module 4: Treatment – drug-resistant tuberculosis treatment. The main focus of the e-course is programmatic; clinical aspects are only discussed when relevant to specific topics.
The e-course comprises 11 sections and a final assessment and uses a combination of short video lectures, exercises, quiz questions and additional reading materials.
- Introduction to the e-learning course
- Rationale for national TB programmes to implement and scale up treatment of DR-TB
- Key considerations in DR-TB treatment
- Treatment regimen for isoniazid-resistant rifampicin-susceptible TB
- Shorter, all-oral bedaquiline-containing treatment regimen
- Longer treatment regimens for multidrug-resistant TB (MDR-TB)/ rifampicin-resistant TB (RR-TB)
- The bedaquiline, pretomanid and linezolid (BPaL) regimen for MDR-TB or RR-TB with additional fluoroquinolone resistance
- Adjuncts to MDR-TB treatment
- Patient support to enable adherence to treatment
- Programmatic implementation of regimens for MDR-TB and RR-TB
- Assessing drug-resistant TB programme implementation effectiveness
- Final assessment